Dr. Deborah Kinch brings 25 years of experience advancing novel drugs in the clinic and expanding value for marketed products. At Homology, Dr Kinch has advanced the pipeline from research to clinical stage through implementation of cross-functional strategies resulting in the successful clearance of INDs for both the gene transfer and gene editing platforms.
Prior to joining Homology, Dr. Kinch served as head of the Early Regulatory Sciences group at Biogen, where she was responsible for overseeing regulatory strategy, establishing strategic direction, and creating value through early regulatory engagement for products spanning research through Phase 2 development. During her 20-year tenure at Biogen, Dr. Kinch held several roles of increasing responsibility in Preclinical and Clinical Development Sciences and in Global Regulatory Sciences and was instrumental in driving products into the clinic and setting foundation for successful transition to pivotal trials. Dr. Kinch holds an A.B. in Biochemistry from Mount Holyoke College and a Ph.D. in Molecular Biophysics and Biochemistry from Yale University.